OMERS ADMINISTRATION Corp Buys New Stake in Merus (NASDAQ:MRUS)

OMERS ADMINISTRATION Corp bought a new position in Merus (NASDAQ:MRUS - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 10,600 shares of the biotechnology company's stock, valued at approximately $446,000.

A number of other large investors have also recently made changes to their positions in the business. Wells Fargo & Company MN increased its holdings in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after buying an additional 300 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Merus by 0.4% in the 4th quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company's stock worth $4,754,000 after buying an additional 416 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Merus by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 52,636 shares of the biotechnology company's stock worth $2,213,000 after buying an additional 540 shares during the last quarter. HighTower Advisors LLC increased its holdings in shares of Merus by 10.9% in the 4th quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company's stock worth $337,000 after buying an additional 789 shares during the last quarter. Finally, Arizona State Retirement System increased its holdings in shares of Merus by 9.6% in the 4th quarter. Arizona State Retirement System now owns 13,833 shares of the biotechnology company's stock worth $582,000 after buying an additional 1,209 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MRUS. HC Wainwright reiterated a "buy" rating and set a $85.00 price target on shares of Merus in a report on Monday, March 3rd. Piper Sandler began coverage on shares of Merus in a report on Thursday, February 13th. They set an "overweight" rating and a $84.00 price target on the stock. Guggenheim reiterated a "buy" rating and set a $109.00 price target on shares of Merus in a report on Friday, March 28th. William Blair reiterated an "outperform" rating on shares of Merus in a report on Monday, April 28th. Finally, Bank of America cut their price target on shares of Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Fourteen analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Merus presently has a consensus rating of "Buy" and an average price target of $86.00.

Merus Price Performance

MRUS stock traded up $13.54 during mid-day trading on Friday, reaching $55.14. The company had a trading volume of 7,872,333 shares, compared to its average volume of 733,508. The company has a market capitalization of $3.82 billion, a PE ratio of -13.96 and a beta of 0.94. The firm has a 50 day moving average of $42.72 and a 200 day moving average of $43.49. Merus has a 12 month low of $33.19 and a 12 month high of $61.28.

Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.23). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $26.49 million during the quarter, compared to analysts' expectations of $7.82 million. Analysts anticipate that Merus will post -3.85 EPS for the current year.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.